Who are Combivir+Kaletra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAF with a boosted protease inhibitor, zidovudine+lamivudine+lopinavir/ritonavir, Combivir+Reyataz, Maternal zidovudine/lamivudine/lopinavir-ritonavir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combivir-kaletra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Combivir+Kaletra — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combivir+Kaletra (Combivir+Kaletra) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + protease inhibitor). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + protease inhibitor) HIV reverse transcriptase and HIV protease Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Combivir+Kaletra (Combivir+Kaletra) — Hospital Clinic of Barcelona. This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Combivir+Kaletra TARGET	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
zidovudine+lamivudine+lopinavir/ritonavir	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease
Combivir+Reyataz	Combivir+Reyataz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase; HIV protease
Maternal zidovudine/lamivudine/lopinavir-ritonavir	Maternal zidovudine/lamivudine/lopinavir-ritonavir	Centers for Disease Control and Prevention	phase 3	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + protease inhibitor) class)

Hospital Clinic of Barcelona · 2 drugs in this class
Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Combivir+Kaletra — Competitive Intelligence Brief. https://druglandscape.com/ci/combivir-kaletra. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab